BioCentury
ARTICLE | Clinical News

Nab-rapamycin: Phase II started

November 9, 2015 8:00 AM UTC

AADi began an open-label, U.S. pivotal Phase II trial to evaluate ABI-009 in about 35 patients. AADi has exclusive, worldwide rights to develop and commercialize ABI-009 from Celgene (see BioCentury, ...